not vested
<Research Report>CSPC PHARMA (01093.HK) rated Buy with target cut to $9.1 by Deutsche
May 26, 2014
Deutsche Bank noted in the latest research report that CSPC PHARMA (01093.HK) first-quarter gross profit margin rose 6.1 ppt yearly to 37.7%, mainly due to the product structure optimization.
The rating is set at Bu, with target price cut from $9.25 to $9.1.
The main risks include slow tender progress, regulatory delays, more intense competition and the loss of the largest shareholders.
Source: AAStocks Financial News